ResQ Pharma Inc.

We have assembled a world-class team uniquely tailored to ensure reliable global access to LipidRescue Therapy (LRT) as the first FDA approved antidote for local anesthetic systemic toxicity (LAST).

Management

Paul Burton JD, MBA

Paul Burton JD, MBA

CEO

Paul Burton is the Chief Executive Officer and a Member of the Board of Directors. As a former investment banker with Citigroup Corporate & Investment Bank in NYC and London, he has helped companies raise over $15 billion in financing.

Chris Bryant

Chris Bryant

Director of Product Development

Chris Bryant is the Director of Product Development. As an experienced biopharmaceutical management professional, Chris brings more than 25 years in R&D management. He is a specialist in biologics development through all phases.

Mukesh Kumar, PhD, RAC

Mukesh Kumar, PhD, RAC

Director of Regulatory Affairs

Mukesh Kumar is the Director of Regulatory Affairs. With his technical, scientific and regulatory background, he excels at developing strategies for nascent biopharmaceutical companies navigating clinical and post-approval regulatory hurdles.

Board of Directors

Paul Burton JD, MBA

Paul Burton JD, MBA

Board Member

Paul Burton is the Chief Executive Officer and a Member of the Board of Directors. As a former investment banker with Citigroup Corporate & Investment Bank in NYC and London, he has helped companies raise over $15 billion in financing.

Guy Weinberg, MD

Guy Weinberg, MD

Founder, Board Member

Guy Weinberg is the founder of ResQ Pharma and the inventor of LipidRescue™ Therapy (LRT). He is a professor of Anesthesiology at the University of Illinois College of Medicine at Chicago and a physician Jesse Brown VA Medical Center.

Francis Wisniewski

Francis Wisniewski

Board Member

Also known as Wiz, Francis is the Managing Partner of Hard 8 Venture Capital. He is also a Co-Founder and Managing Partner of Hard Eight Futures, LLC. He is a Chicago-based serial entrepreneur and investor with extensive experience advising startups.

Todd Beck

Todd Beck

Board Member

Todd Beck is the Founder & CEO of Beck Media & Marketing. Based in Santa Monica, CA, Beck Media clients include Twitter, NBCUniversal, AmazonPrime, Hulu and the Academy of Motion Pictures Arts & Sciences among others.

Antoinette Gawin

Antoinette Gawin

Board Member

Antoinette Gawin is a former senior executive at Baxter International and GE Healthcare. Currently, she is the EVP of Global Commercial at TerumoBCT.

Paul Hertz

Paul Hertz

Board Member, Co-Founder, Co-Inventor

Paul Hertz is the Co-founder of ResQ Pharma and co-inventor of LipidRescue™ Therapy (LRT). He is a practicing anesthesiologist and a former Professor at the University of Illinois College of Medicine.

Scientific Advisory Board

Guy Weinberg, MD

Guy Weinberg, MD

Scientific Advisor

Guy Weinberg is the founder of ResQ Pharma and the inventor of LipidRescue™ Therapy (LRT). He is a professor of Anesthesiology at the University of Illinois College of Medicine at Chicago and a physician Jesse Brown VA Medical Center.

Paul Hertz

Paul Hertz

Scientific Advisor

Paul Hertz is the Co-founder of ResQ Pharma and co-inventor of LipidRescue™ Therapy (LRT). He is a practicing anesthesiologist and a former Professor at the University of Illinois College of Medicine.

Steven Shafer, MD

Steven Shafer, MD

Scientific Advisor

Steven Shafer is a professor of Anesthesiology at Stanford University Medical Center. As the former Chair of the FDA’s Anesthetic and Life Support and Drug Advisory Committee, Shafer’s experience is invaluable. He is also a member of Stanford Medical Center’s IRB.

ResQ Pharma’s CIMs Team

Joe Luminiello

Joe Luminiello

Advisor

Joe Luminiello, a former Takeda executive, advises life science companies and has co-founded an intellectual property accelerator to help inventors commercialize technologies in the life science and healthcare verticals. He provides operational and strategy guidance.

Catherine Sazdanoff

Catherine Sazdanoff

Advisor

Catherine Sazdanoff is the Chief Business Officer at Strata Oncology and a deeply experienced executive with specialties in guiding businesses in complex and highly-regulated industries. She combines insightful strategic development with decisive execution. 

Eric Waehner, MBA

Eric Waehner, MBA

Advisor

Since 1998, Eric Waehner has worked in the pharmaceutical and biomedical verticals. As the Senior Director for Commercial Transactions at Takeda Pharmaceuticals, Waehner ensures that Takeda evaluates and acquires innovative life science companies.

Gary Winer, MBA

Gary Winer, MBA

Advisor

Gary Winer is an experienced global healthcare management executive. He has led international operations at Abbott, Pfizer and Abbvie. His forte is implementing effective international growth strategies to successfully launch new products.

ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue™ Therapy for the Treatment of Local Anesthetic Systemic Toxicity

ResQ Pharma Receives FDA’s ODD status for LipidRescue Therapy (LRT) for LAST and on track to file NDA in first half of 2018

Read More

ResQ Pharma’s CEO, Paul Burton to Present at Biotech Showcase

Paul Burton, the CEO of ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings is scheduled to present at Biotech Showcase as part of the J.P. Morgan 35th Annual Healthcare Conference Week in San Francisco.

Read More

ResQ Pharma Raises $725,000

ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings, announces the completion of a second seed-round of equity financing of $725,000.00.

Read More

Guy Weinberg Presents at EAPCCT

ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced that Guy Weinberg, M.D., its co-founder and inventor of LRT will be presenting this Friday, May 27th at the Congress Of The European Association Of Poisons Centres And Clinical Toxicologists

Read More